GUANINE NUCLEOSIDES--POTENTIAL NEW THERAPEUTIC USES
鸟嘌呤核苷——潜在的新治疗用途
基本信息
- 批准号:2103023
- 负责人:
- 金额:$ 10.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1994
- 资助国家:美国
- 起止时间:1994-01-01 至 1998-12-31
- 项目状态:已结题
- 来源:
- 关键词:DNA repair Hodgkin's disease acute lymphocytic leukemia adduct alkylating agents animal tissue cell cycle cytotoxicity deoxyribonucleoside triphosphate gel electrophoresis guanine nucleoside high performance liquid chromatography human tissue immunomodulators lymphoma melphalan neoplasm /cancer pharmacology purine nucleoside phosphorylase tissue /cell culture
项目摘要
Inhibition of DNA synthesis by a deoxynucleoside or a deoxynucleoside
analogue can kill cells ("direct toxicity") and can also enhance the
toxicity of alkylating agents ("sensitization"). Not surprisingly, the
extent of direct toxicity correlates closely with the degree of
sensitization. This proposal addresses T cell neoplasms which are
unusually sensitive to direct toxicity by deoxyguanosine and uniquely and
exquisitely sensitive to its analogue 9-beta-D-arabinofuranosylguanine
("araG"). One objective of this proposal is to use this unique
sensitivity to selectively sensitize T cell neoplasms compared to normal
hematopoietic progenitor cells responsible for dose-limiting clinical
toxicity. Such T cell selective sensitization has clear potential
applications in clinical treatment as well as in ex vivo purging of
neoplastic T cells from bone marrow. A second objective is to determine
the mechanisms of sensitization with the long term intention of
extrapolating these mechanistic concepts to closely analogous
sensitization approaches.
In preliminary studies araG and deoxyguanosine did potently enhance
alkylator toxicity producing 5 to 8 fold dose modifying effects in human
T cell neoplasms but not in B cells. In sharp contrast, guanosine was non-
toxic and strongly protected against alkylator toxicity in human T cell
lines - despite depleting dCTP and dTTP pools to the same extent as did
equimolar deoxyguanosine. Guanosine's surprising effect and the very
different effect of araG may relate to metabolism of araG almost
exclusively via the deoxycytidine kinase ("dCK") pathway and to metabolism
of guanosine via the purine nucleoside phophorylase ("PNP") pathway.
Deoxyguanosine, metabolized via both pathways, might sensitize T cell
neoplasms (high dCK:PNP ratio) while simultaneously protecting non-T cells
(low dCK:PNP). Using measures of nucleoside metabolism, DNA injury and
repair, and new techniques for specifically identifying which aspects of
DNA synthesis are being impaired, this proposal will test l) whether
deoxyguanosine, araG or guanosine preferentially sensitize or protect
human T cell malignancies relative to non-T cells including normal marrow
progenitor cells, 2) whether deoxyguanosine can sensitize or protect
depending on its metabolism via the dCK or PNP pathways, 3) whether
guanosine protects by increasing guanylate ribonucleotides which then
block cell cycle progression permitting greater repair of alkylator-
injured DNA before cells initiate replicative synthesis, and 4) whether
deoxyguanosine and araG cause direct toxicity and sensitization not only
by depleting dCTP and dTTP but also by high dGTP and araGTP inhibiting DNA
polymerases alpha, delta or epsilon.
通过脱氧核苷或脱氧核苷抑制DNA合成
模拟可以杀死细胞(“直接毒性”),也可以增强
烷基化剂的毒性(“敏化”)。 毫不奇怪,
直接毒性的程度与程度紧密相关
致敏。该建议解决了T细胞肿瘤
对脱氧鸟苷的直接毒性异常敏感,唯一的
对其类似物9-beta-d-arabinofuranosylguanine非常敏感
(“ Arag”)。 该提议的一个目的是使用此独特
与正常人相比,对选择性敏化T细胞肿瘤的敏感性
负责剂量限制临床的造血祖细胞
毒性。这样的T细胞选择性敏化具有明显的潜力
在临床治疗中的应用以及在体外清除
来自骨髓的肿瘤T细胞。第二个目标是确定
长期意图的致敏机制
将这些机械概念推断为紧密相似
致敏方法。
在初步研究中
烷基毒性在人类中产生5至8倍剂量的修饰作用
T细胞肿瘤,但不在B细胞中。相比之下,鸟嘌呤是非 -
有毒并强烈保护人类T细胞中的烷基毒性
线 - 尽管DCTP和DTTP池耗尽的程度与以下情况相同
等摩尔脱氧藻氨酸。鸟嘌呤的令人惊讶的效果和
ARAG的不同作用几乎与Arag的代谢有关
专门通过脱氧胞苷激酶(“ DCK”)途径和代谢
通过嘌呤核苷哲学酶(“ PNP”)途径的鸟嘌呤。
通过两种途径代谢的脱氧鸟苷可能使T细胞敏感
肿瘤(高DCK:PNP比),同时保护非T细胞
(低DCK:PNP)。使用核苷代谢,DNA损伤和
维修和新技术,以专门识别
DNA合成受到损害,该建议将测试l)
脱氧鸟苷,Arag或鸟苷优先敏感或保护
相对于非T细胞(包括正常骨髓)的人类T细胞恶性肿瘤
祖细胞,2)脱氧鸟苷是否可以敏感或保护
取决于其通过DCK或PNP途径的代谢,3)是否是否
鸟苷通过增加鸟苷酸核糖核苷酸来保护,然后
阻止细胞周期进程,允许对烷基烷基的修复进行更大的修复
细胞启动重复合成之前受伤的DNA,4)是否是否
脱氧鸟苷和Arag不仅引起直接毒性和敏感性
通过耗尽DCTP和DTTP,但也可以通过高DGTP和ARAGTP抑制DNA
聚合酶alpha,delta或epsilon。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JUSTIN D COHEN其他文献
JUSTIN D COHEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JUSTIN D COHEN', 18)}}的其他基金
GUANINE NUCLEOSIDES--POTENTIAL NEW THERAPEUTIC USES
鸟嘌呤核苷——潜在的新治疗用途
- 批准号:
2633865 - 财政年份:1994
- 资助金额:
$ 10.57万 - 项目类别:
GUANINE NUCLEOSIDES--POTENTIAL NEW THERAPEUTIC USES
鸟嘌呤核苷——潜在的新治疗用途
- 批准号:
2008384 - 财政年份:1994
- 资助金额:
$ 10.57万 - 项目类别:
GUANINE NUCLEOSIDES--POTENTIAL NEW THERAPEUTIC USES
鸟嘌呤核苷——潜在的新治疗用途
- 批准号:
2103024 - 财政年份:1994
- 资助金额:
$ 10.57万 - 项目类别:
GUANINE NUCLEOSIDES--POTENTIAL NEW THERAPEUTIC USES
鸟嘌呤核苷——潜在的新治疗用途
- 批准号:
2103025 - 财政年份:1994
- 资助金额:
$ 10.57万 - 项目类别:
相似国自然基金
人巨细胞病毒与Hodgkin病发病关系的研究
- 批准号:30270577
- 批准年份:2002
- 资助金额:20.0 万元
- 项目类别:面上项目
相似海外基金
Genotoxicity & Emergence of Genome Instability in Humans
遗传毒性
- 批准号:
6612527 - 财政年份:2003
- 资助金额:
$ 10.57万 - 项目类别:
AUTOLOGOUS BONE MARROW TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCY
自体骨髓移植治疗血液恶性肿瘤
- 批准号:
6102095 - 财政年份:1999
- 资助金额:
$ 10.57万 - 项目类别:
IN VIVO SOMATIC MUTATIONS IN CHILDREN WITH CANCER
癌症儿童体内体细胞突变
- 批准号:
6173638 - 财政年份:1998
- 资助金额:
$ 10.57万 - 项目类别:
IN VIVO SOMATIC MUTATIONS IN CHILDREN WITH CANCER
癌症儿童体内体细胞突变
- 批准号:
6376745 - 财政年份:1998
- 资助金额:
$ 10.57万 - 项目类别:
IN VIVO SOMATIC MUTATIONS IN CHILDREN WITH CANCER
癌症儿童体内体细胞突变
- 批准号:
2896469 - 财政年份:1998
- 资助金额:
$ 10.57万 - 项目类别: